Syngene International Ltd. · NSE:SYNGENE
Syngene International — Q3 FY25 Earnings Presentation
34 slides from Syngene International's earnings presentation, Jan 23, 2025
Slide 1: Regulation 30 cover letter to stock exchanges
Ref: Syn/CS/SE/IP/2024-25/Jan/10 Syngene International Limited Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area, IV Phase, Jigani Link Road, Bengaluru 560099, Karnataka, India. T +91 80 6891 8000 F +91 80 6891 8808 CIN: L85110KA1993PLC014937 www.syngeneintl.com January 23, 2025 T
Slide 2: Investor Presentation January 2025
Investor Presentation January 2025
Slide 3: Safe harbour
Safe harbour Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements
Slide 4: Contents
Contents 1 Q3 FY25 Highlights 2 Syngene – Putting Science to Work 3 Syngene strengths 4 Financials 5 Shareholding and Share Information Putting Science to Work 3
Slide 5: Q3 and 9M FY25 Highlights
Al Q3 and 9M FY25 Highlights Syngene
Slide 6: Q3 and 9M FY25 performance
Q3 and 9M FY25 performance Operating Highlights Q3 FY25 Financial Highlights Revenue from Operations • Third quarter performance was marked by growth in the Research Operating EBITDA margin Rs 944 Crs ( 11% YoY) Services as well as CDMO business with increased traction in 30% (27% in Q3FY24) (USD* 1
Slide 7: Syngene – Putting Science to Work
2 Syngene – Putting Science to Work
Slide 8: Partner in innovation: #Putting science to work
Partner in innovation: #Putting science to work Who we are and what we do We aim to be a world class partner delivering innovative scientific solutions for clients We offer integrated Sector expertise include Our team includes more Established track record in solutions across pharmaceuticals, biotec
Slide 9: Our journey so far
Our journey so far 2019 – 2024 Globalization and strategic collaboration Continued investments and growth • Expanded collaboration with • Expanded into formulations development BMS, Amgen and Zoetis • Contract with Endo Pharmaceuticals to develop novel anti cancer • Expansion of Integrated Drug Disc
Slide 10: Key facts and figures
Key facts and figures 400+ 14 out of top 20 pharma 400+ World class active clients patents companies are clients held with clients infrastructure 3 campuses in Bangalore, Hyderabad and Mangalore qualified to meet international standards Rs. 3,489 Cr Rs. 519 Cr** 8,146 headcount 82% (US$418* Mn) ener
Slide 11: Our Strategy
Our Strategy Research: Dedicated Research: Discovery Centers Services Continue to build our current Operational Excellence Provide end-to-end discovery and collaborations with Amgen, Bristol Drive operational excellence through preclinical development capabilities, Myers Squibb (BMS), and Baxter imp
Slide 12: Twin engine growth strategy – with broad capabilities spanning the value chain
Twin engine growth strategy – with broad capabilities spanning the value chain Research Services (CRO) Development and Manufacturing Services (CDMO) Discovery Services Dedicated R&D Centers Development Services Manufacturing Services Flexible Platform with capability across Ring-fenced infrastructur
Slide 13: Sustained investments in business and world class infrastructure
Sustained investments in business and world class infrastructure: a catalyst for expanded client base and strong revenue growth Strong revenue growth and Growing Increasing High Growing Increasing increasing Infrastruc Client Revenue ture infrastructure Base client base Growth revenue per employee M
Slide 14: Strategic investments augment cash flows and EPS, driving shareholder returns
Strategic investments augment cash flows and EPS, driving consistent shareholder returns Growing Increasing Increasing Increasing High High Cash Improving EPS Infrastruc operating cash Client Flow market Revenue Soaring ture flow Base Growth Market capitalization Capitaliza tion EPS* more than doubl
Slide 15: Syngene strengths
3 Syngene strengths Syngene
Slide 16: Syngene strengths
Syngene strengths A global scale CRO/CDMO Solutions through innovation Quality matters • Integrated Drug Discovery, Development and • IP fully assigned to clients • Fully digitized quality organization Manufacturing service provider • Track record of data management and • Strong compliance track rec
Slide 17: Our end-to-end platform: one-stop-shop for discovery, development and manufacturing
Our end-to-end platform enables us to be a 'one-stop-shop' for discovery, development and manufacturing (small molecules and biologics) Discovery Development Manufacturing Chemistry Drug Substance Clinical Supplies Small Drug Product Molecules Biology Biologics Integrated Drug Substance – Drug Produ
Slide 18: Experienced workforce: building capabilities and careers
Experienced workforce: building capabilities and careers 8,146 Inspiring technical excellence and providing opportunities to grow total headcount Nurturing young • Syngene Training Academy offers new graduate recruits a six-month extended induction to help 5,656 scientists delivering talent and them
Slide 19: Extended our state-of-the-art infrastructure and new capabilities
Extended our state-of-the-art infrastructure & new capabilities in different locations within India to meet our strategic partners needs… HQ campus at Bangalore, India 90 Acres (3,64,217 sq. mt) where most of Syngene’s capabilities are housed today Fully functional R&D Centre at Genome Valley, Hyder
Slide 20: We currently operate a range of successful collaboration models
We currently operate a range of successful collaboration models Dedicated R&D Labs Full time equivalent (FTE) Fee For service (FFS) Risk-reward • Dedicated scientific resources • Dedicated scientific and support • Flexible, on-demand resources with • Rewards based on clearly defined, selected from p
Slide 21: Our experience spans multiple industry segments and global leaders
Our experience spans multiple industry segments and partners us with global leaders across the world… Large & Mid-Sized Emerging Chemicals/ BioPharma BioPharma (EBP) Animal Health AgroChem CPG Polymers Putting Science to Work 20
Slide 22: Operational robustness driving strategy execution
Operational robustness driving strategy execution Continuous improvement embedded in operations driven by Focused execution through strong Project certified operational leaders Management Six Sigma Black Belt certified staff in each Structured program management for executing client service line and
Slide 23: Harnessing digitization and automation through our Lab 4.0 strategy
We are harnessing digitization and automation through our Lab 4.0 strategy At Syngene, we have adopted Lab 4.0, deploying technology for compliance, Certification as per ISO 13485:2016, ISO/IEC as an optimizer and as an augmenter 27001 and ISO 9001:2015 requirements Online management of specificatio
Slide 24: Committed to safety and sustainability
Committed to safety and sustainability Committed to environmental protection Safety is our first priority • Committed to Science-based targets for greenhouse gases • Accredited with ISO 45001:2018 for Occupational Health and • 96% of total hazardous and non-hazardous Safety (OH&S) measures waste rec
Slide 25: International accreditations
International accreditations • USFDA,OHSAS 18001 • GLP, cGMP, AAALAC & CPCSEA Certified facilities • CAP accreditation, ISO/IEC 27001:2013 accreditation • EMA and PMDA approved, AAALAC accredited facility • The safety assessment laboratories and large molecule bioanalytical lab are ISO IEC 17025:201
Slide 26: Industry recognition for scientific capability and business excellence
We have consistently received industry recognition for our scientific capability and business excellence • CMO Leadership Awards 2022 Presented by Life Science Leader and Outsourced Pharma • CMO Leadership Award Champion 2022 - Presented by Life Science Leader and Outsourced • CMO Leadership Award W
Slide 27: Robust risk management framework
Robust risk management framework Syngene has a risk management framework to identify, monitor, report and manage risk Every risk owner monitors and manages risks relevant to their area of responsibility Executive Committee (EC) Board of Directors(BOD) • Sign-off on Enterprise Risk Framework annually
Slide 28: Financials
4 Financials
Slide 29: Q3FY25 financial highlights
Q3FY25 financial highlights All figures in Rs. Mn unless otherwise specified Particulars Q3 FY24 Q3 FY25 YoY change Q2 FY25 QoQ change Balance Sheet Highlights Revenue from operations 8,535 9,437 11% 8,910 6% As on 31st December 2024 Other income 293 183 -38% 165 11% Shareholders’ funds 44,820 Repo
Slide 30: 9 months FY25 financial highlights
9 months FY25 financial highlights All figures in Rs. Mn unless otherwise specified Particulars 9M FY24 9M FY25 YoY change Revenue from operations 25,717 26,244 2% Other income 745 529 -29% Reported revenue 26,462 26,773 1% Material costs 7,274 7,075 -3% Staff costs 7,170 7,999 12% Other direct c
Slide 31: Shareholding and Share Information
Shareholding and Share 5 Information
Slide 32: Syngene and Biocon Group
Syngene and Biocon Group Syngene is an operationally independent publicly listed Biocon Limited, founded in 1978, is an innovation-led global subsidiary of Biocon Limited, established in 1993 as India’s biopharmaceuticals company and has majority holding in key first Contract Research Organization.
Slide 33: Shareholding and Share Information
Shareholding and Share Information Syngene’s shareholders* Syngene’s Share Information* NSE Ticker SYNGENE 1% BSE Ticker 539268 Promoter & Promoter Group Market Cap (Rs. Mn) 3,45,558 47% 53% Public % free-float^ 47% ESOP Trust Free-float market cap (Rs. Mn) 1,63,300 Share Outstanding (Mn) 403 • As o
Slide 34: For more details
For more details Visit our website www.syngeneintl.com https://twitter.com/SyngeneIntl https://www.linkedin.com/company/syngene-international-limited https://www.facebook.com/syngeneintl/ https://www.youtube.com/channel/UCIC4WSA1k5YAC531gMLkbIQ IR Contact: Media Contact: Krishnan G/ Nandini Agarwal
Syngene International — Q3 FY25 Earnings Presentation on 6ix